CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Two-Year Outcomes After Sirolimus-Eluting Stent Implantation
Results From the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) Trial
Giora Weisz, MD*,
Martin B. Leon, MD*,*,1,
David R. Holmes, Jr, MD ,
Dean J. Kereiakes, MD ,
Mel R. Clark, MD ,
Barry M. Cohen, MD¶,2,
Stephen G. Ellis, MD||,3,
Patrick Coleman, MD#,
Carolyn Hill**,
Chunxue Shi, MS,
Donald E. Cutlip, MD,
Richard E. Kuntz, MD, MSc and
Jeffrey W. Moses, MD*,4
* Cardiovascular Research Foundation and Columbia University Medical Center, New York, New York
Saint Mary’s Hospital, Rochester, Minnesota
Ohio Heart Health Center, Cincinnati, Ohio
Intergris Oklahoma Heart Center, Oklahoma City, Oklahoma
¶ Morristown Memorial Hospital, Morristown, New Jersey
|| Cleveland Clinic Foundation, Cleveland, Ohio
# Northern California Research Association, Santa Rosa, California
** Cordis (Johnson & Johnson), Warren, New Jersey
Harvard Clinical Research Institute, Boston, Massachusetts
Beth Israel Deaconess Medical Center, Boston, Massachusetts
Brigham and Women’s Hospital, Boston, Massachusetts
Manuscript received January 9, 2005;
revised manuscript received October 28, 2005,
accepted November 7, 2005.
* Reprint requests and correspondence: Dr. Martin B. Leon, Center for Interventional Vascular Therapy, Columbia University Medical Center, Herbert Irving Pavilion, 161 Fort Washington Avenue, 5th Floor, New York, New York 10032. (Email: mleon{at}crf.org).
 |
Abstract
|
|---|
OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study.
BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS).
METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years.
RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8% and 21.3% in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1% versus 24.4% and 12.0% versus 26.7%, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups.
CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.
|
Abbreviations and Acronyms
| | BMS = bare-metal stents | | LAD = left anterior descending coronary artery | | MACE = major adverse cardiac event | | PES = paclitaxel-eluting stents | | SES = sirolimus-eluting stents | | SIRIUS = Sirolimus-Eluting Stent in De Novo Native Coronary Lesions | | TLR = target lesion revascularization | | TVF = target vessel failure | | TVR = target vessel revascularization |
|
In multiple blinded randomized clinical trials, drug-eluting stents (containing sirolimus or paclitaxel) have shown significant improvement in angiographic and clinical outcomes compared with bare-metal stents (BMS) (1–9). However, there are sparse data supporting the long-term benefits of drug-eluting stents in patients with coronary lesions beyond the first year after stent implantation (10,11). The Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) multicenter blinded randomized trial examined the safety and efficacy of sirolimus-eluting stents (SES) in 1,058 patients, and results up to one year indicated significant reduction in both restenosis and target lesion revascularization (TLR) (2,3). This report extends the clinical follow-up of the original SIRIUS patient cohort to determine if the early and middle-term safety and efficacy of SES is maintained at two years.
|
Methods
|
|---|
Study design and eligibility criteria.
The methods of the SIRIUS trial were previously reported (2). Patients enrolled in the study had a clinical history of angina and single coronary target lesions, 15 to 30 mm in length, in vessels 2.5 to 3.5 mm in diameter. Major exclusion criteria included recent myocardial infarction, left ventricular ejection fraction <25%, target lesion in an ostial or bifurcation location, or a thrombotic or severely calcified lesion.
Data collection and follow-up.
Patients had clinical evaluations at 30 days and 6, 9, 12, and 24 months. Two-year clinical follow-up was supervised by the physician investigators and the study coordinators from each of the enrolling sites. Patients were queried by telephone interview, and in the case of clinical events, source medical documents were retrieved and reviewed and adjudicated by an independent Clinical Events Committee blinded to the treatment assignment. Complete data compliance for all two-year follow-up end points was 91.6% for the BMS group and 92.3% for the SES group.
Study end points.
This two-year follow-up study focuses on clinical restenosis or TLR, defined as the need for clinically driven repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel. Clinical indications for repeat revascularizations included a positive noninvasive functional study, ischemic electrocardiogram changes at rest in a distribution consistent with the target vessel, or ischemic symptoms and an in-lesion diameter stenosis by quantitative coronary angiography of  50%. In addition, in the absence of the aforementioned objective criteria for ischemia, an in-lesion diameter stenosis by quantitative coronary angiography of 70% was also considered of sufficient severity to justify repeat revascularization. The independent Clinical Events Committee blindly adjudicated all clinically driven revascularization episodes. The SIRIUS secondary clinical end points included non-TLR target vessel revascularization (TVR), target vessel failure (TVF), and major adverse cardiac events (MACE). The definitions of these end points have been previously described (2).
Early stent thrombosis, either acute (within 24 h) or subacute (between 24 h and 30 days), was defined as angiographic documentation of target vessel occlusion or any death or myocardial infarction occurring within 30 days that is not clearly related to causes other than stent occlusion. The protocol definition of late stent thrombosis was myocardial infarction occurring >30 days after the index procedure and attributable to the target vessel, angiographic documentation (site-reported or by quantitative coronary angiography) of thrombus or total occlusion of the target site, and freedom from an interim revascularization of the target vessel. This very stringent definition represents definite late stent thrombosis. For the purposes of this report, we have extended the definition of late stent thrombosis to include additional categories of possible and cannot exclude late stent thrombosis. The definition of possible late stent thrombosis includes patients with myocardial infarction occurring >30 days after the index procedure and attributable to the target vessel, no identifiable "culprit" lesion elsewhere, and freedom from an interim revascularization of the target vessel. The definition of cannot exclude late stent thrombosis includes patients with sudden cardiac death >30 days after the index procedure, no identifiable "culprit" lesion elsewhere (as suggested by nontarget vessel electrocardiogram changes or autopsy evidence of a patent target vessel), and freedom from interim TVR.
Statistical analysis.
The effectiveness analysis and the safety evaluation were performed on a modified intent-to-treat population; de-registered patients were not included in the analysis because they received neither study treatment.
Continuous variables are summarized as means and standard deviations and compared between treatment groups using t test. Categorical variables are summarized as frequencies and percentages and compared between treatment groups using the Fisher exact test. Out-of-hospital outcomes are summarized as Kaplan-Meier event rates and compared between treatment groups using log-rank tests. All tests are two-sided with a significance level of 0.05. Multivariate predictors were identified by using a Cox model with an entry/stay criteria of 0.10/0.15. All statistical analyses were performed with SAS software (version 6.12; SAS Institute, Cary, North Carolina).
|
Results
|
|---|
As previously reported, both groups had similar baseline clinical and angiographic characteristics, procedural factors, and acute (in-hospital) results (2).
Long-term clinical outcomes.
At two years, the significant differences between the SES and BMS groups in TLR, TVR, TVF, and MACE were all maintained (Table 1, Fig. 1). There were small increases in both groups and still no differences in death or myocardial infarction. The specific etiologies of all-cause mortality between one and two years, included cardiac deaths in two patients (chest pain followed by cardiac arrest, one case in each group) and noncardiac deaths in five patients (one case of documented noncardiac sudden death in the SES group, two deaths due to severe chronic lung disease in the SES group, and two deaths due to malignancy in the control group). There were infrequent late TLR events in both groups between one and two years (0.9% for SES and 1.3% for control stents), and the magnitude of reduction in clinical restenosis was the same at one and two years (TLR 5.8% for SES group and 21.3% for controls at two years; p < 0.001).
View larger version (27K):
[in this window]
[in a new window]
|
Figure 1 Kaplan-Meier event-free survival at two years for target lesion revascularization (TLR), major adverse coronary events (MACE), and target vessel failure (TVF). p < 0.001 for all comparisons of sirolimus-eluting stent (SES) vs. control bare-metal stent.
|
|
Various higher restenosis-risk patient and lesion subgroups (including diabetes, left anterior descending coronary artery [LAD] lesion location, small vessel size, and long lesion length) were examined by univariate analysis (Fig. 2). In all cases, the significant reduction in TLR associated with SES compared with BMS controls in these selected subgroups was maintained at two years. Factors that predicted TLR at two years were evaluated using multiple logistic regression analysis in the entire study group and in the SES group alone. In the entire study group, independent predictors of TLR included assignment to sirolimus treatment (hazard ratio [HR] 0.21; p < 0.001), reference vessel diameter (HR 0.55; p < 0.02), diabetes mellitus (HR 1.56; p = 0.03), LAD location (HR 1.06; p = 0.03), and total stent length (relative 3% increase in risk for each 1-mm increase in stent length; p < 0.0001).
View larger version (24K):
[in this window]
[in a new window]
|
Figure 2 Odds ratios for target lesion revascularization at 720 days for the overall population and by subgroup. Values represent event rates (%) in each arm by subgroup. Bars represent odds ratio point estimates and 95% confidence intervals (CI). LAD = treatment of lesions in the left anterior descending artery.
|
|
Stent thrombosis episodes (definite, possible, and cannot exclude) were distributed into early events (up to 30 days after the index procedure), late events up to 1 year, and late events between 1 and 2 years for both the SES and the control patients (Table 2). Early stent thrombosis and definite late stent thrombosis up to one year was observed in two SES patients (0.4%) and in four control patients (0.8%). Definite late stent thrombosis between one and two years was seen in one additional SES patient and in no control patients (overall definite stent thrombosis frequency up to two years was 0.6% for SES and 0.8% for control; nonsignificant difference). Possible late stent thrombosis occurred in no SES patients and in two control patients (one between 30 days and 1 year and one between 1 and 2 years). Cannot exclude late stent thrombosis occurred in two SES patient (one between 30 days and 1 year and one between 1 and 2 years) and in two control patients (one between 30 days and 1 year and one between 1 and 2 years). Overall cumulative stent thrombosis (including all categories of late stent thrombosis) up to two years after the index procedure occurred in five SES (0.9%) and in eight control BMS patients (1.5%, p = 0.11).
|
Discussion
|
|---|
Over the past two years, since the introduction of drug-eluting stents into the U.S., there has been an evolving change in the treatment paradigm such that the vast majority of current patients receive SES or paclitaxel-eluting stents (PES) during percutaneous coronary interventions. Studies examining angiographic, intravascular ultrasound, and clinical end points have demonstrated safety and efficacy of these devices during the first year after therapy (1–9,12,13). Long-term follow-up after drug-eluting stent implantation is only available for small numbers of patients with focal uncomplicated lesion morphologies (10,11). Therefore, rigorous late clinical follow-up of the earliest patient cohorts from large randomized clinical trials exposed to drug-eluting stents becomes essential to ensure patient safety and to determine if antirestenosis efficacy is maintained. The major findings of this two-year follow-up report involving patients treated with SES from the SIRIUS trial are: 1) clinical restenosis (with blinded adjudication of all clinically driven TLR events) shows maintained antirestenosis efficacy; and 2) late complications such as stent thrombosis between one and two years were rare and occurred with similar frequency in SES and BMS groups.
The concern of late restenosis (after 6 to 12 months) with potent antiproliferative therapies derives from experiences with intravascular radiation (vascular brachytherapy) which was introduced for the prevention of recurrent in-stent restenosis. Despite the significant short-term efficacy of vascular brachytherapy systems (14–18), long-term follow-up results have been less gratifying. A small series of patients with serial angiography and intravascular ultrasound demonstrated relatively early "catch-up" or delayed restenosis (manifested as increased late-loss lumen loss) between 6 and 12 months after beta-vascular brachytherapy (19). More importantly, the five-year follow-up of the gamma-vascular brachytherapy Washington Radiation for In-Stent Restenosis Trial (WRIST) (in-stent restenosis patients) showed that between 6 and 60 months, patients treated with intravascular radiation compared with placebo had four times greater late TLR (21.6% vs. 4.7%; p = 0.04) (20). This late "catch-up" or delayed restenosis phenomena has also been observed with some of the earlier drug-eluting stents. In a small study involving in-stent restenosis patients, the QuaDS-QP2 stent (polymer sleeve eluting a taxane derivative, Quanam Medical Corp., Santa Clara, California) resulted in excellent reduction in restenosis at 6 months, but marked deterioration in angiographic and clinical outcomes after 12-month evaluations (21). The current analysis from the SIRIUS trial, the largest randomized study (1,058 patients) treating patients with SES (2), is particularly meaningful because there was no evidence of disproportionate late clinical events with SES, including death, myocardial infarctions, stent thrombosis, and repeat revascularizations after two-year follow-up (Table 1, Fig. 1).
A recent report (22) has raised concerns that PES and SES may be associated with an increased frequency of late stent thrombosis episodes, in the setting of cessation of antiplatelet therapy. A total of four patients (two with SES and two with PES) experienced late stent thrombosis (at least six months after the index procedure), within days after the cessation of all antiplatelet therapy (both aspirin and clopidogrel). In three of these four patients, the thrombotic episodes were during or after surgical or endoscopic procedures, and in two of the patients stent thrombosis was only in the drug-eluting stent target vessel, whereas BMS in other vessels were confirmed to be patent. Based on these concerns, the SIRIUS patients were analyzed in far greater detail employing an expanded definition of late stent thrombosis to include those patients without angiographic documentation of stent thrombus or occlusion and even in those patients with unexplained sudden cardiac death (Table 2). Of note, dual antiplatelet therapy using aspirin and clopidogrel was maintained for only three months in SIRIUS patients, whereupon the aspirin was routinely continued and the clopidogrel was stopped. Overall, we could not determine any differences in definite, possible, and cannot exclude late stent thrombosis (up to two years) when comparing the SES and BMS treated patients. Cumulative overall stent thrombosis using the less rigorous definitions was 0.9% in SES patients and 1.5% in control patients (p = 0.11). Interestingly, there were two episodes of possible late stent thrombosis that occurred in the BMS group, one soon after cessation of aspirin therapy in a woman anticipating a scheduled elective hysterectomy (clopidogrel had already been stopped months previously) and another during noncardiac surgery after both aspirin and clopidogrel had been stopped. Thus, although we recognize that late stent thrombosis will continue to be a carefully scrutinized clinical complication after drug-eluting stent implantation, especially in an environment where more complex lesion subsets are being treated, we cannot ascertain in the SIRIUS trial any differences in overall and late stent thrombosis between SES and BMS.
Conclusions.
The maintained clinical safety and improved efficacy at two years in SIRIUS patients should provide some confidence that late untoward events are unlikely to be associated with SES. Nevertheless, the SIRIUS trial only included patients with intermediate lesion complexity, and the results cannot be extrapolated to all patient subsets and lesion subgroups. Therefore, additional clinical data are required in more complex patients and lesions to make categorical statements about long-term safety and efficacy of SES. Importantly, annual follow-up of the SIRIUS patients will continue for five years to provide further assurance that this frequently utilized and important interventional device fulfills the most rigorous standards of long-term safety and efficacy.
|
Footnotes
|
|---|
1 Dr. Leon is supported by a Cordis research grant and holds stock in Johnson & Johnson. 
2 Dr. Cohen is a member of the Cordis speakers bureau and holds stock in Johnson & Johnson.
3 Dr. Ellis has received a consulting fee from Cordis.
4 Dr. Moses has received a consulting fee from Cordis and holds stock in Johnson & Johnson.
|
References
|
|---|
1. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 2002;346:1773-1780.[Abstract/Free Full Text]2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 2003;349:1315-1323.[Abstract/Free Full Text] 3. Holmes Jr. DR, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS triala randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.[Abstract/Free Full Text] 4. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteriesdouble-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-1099.[CrossRef][Web of Science][Medline] 5. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) J Am Coll Cardiol 2004;43:1110-1115.[Abstract/Free Full Text] 6. Grube E, Silber S, Hauptmann KE, et al. TAXUS Isix- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.[Abstract/Free Full Text] 7. Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions Circulation 2003;108:788-794.[Abstract/Free Full Text] 8. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 2004;350:221-231.[Abstract/Free Full Text] 9. Stone GW, Ellis SG, Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stentthe TAXUS-IV trial. Circulation 2004;109:1942-1947.[Abstract/Free Full Text] 10. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries Circulation 2003;107:381-383.[Abstract/Free Full Text] 11. Fajadet J, Morice MC, Bode C, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stentsthree-year results of the RAVEL trial. Circulation 2005;111:1040-1044.[Abstract/Free Full Text] 12. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteriesa quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001;103:192-195.[Abstract/Free Full Text] 13. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stentsone-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011.[Abstract/Free Full Text] 14. Teirstein PS, Massullo V, Jani S, et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting N Engl J Med 1997;336:1697-1703.[Abstract/Free Full Text] 15. Waksman R, White RL, Chan RC, et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis Circulation 2000;101:2165-2171.[Abstract/Free Full Text] 16. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting N Engl J Med 2001;344:250-256.[Abstract/Free Full Text] 17. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis Circulation 2002;106:1090-1096.[Abstract/Free Full Text] 18. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosisthe INHIBIT randomised controlled trial. Lancet 2002;359:551-557.[CrossRef][Web of Science][Medline] 19. Munoz JS, Feres F, Abizaid A, et al. Long-term efficacy of intracoronary beta-radiation for the treatment of in-stent restenosisan angiographic and intravascular ultrasound analysis of the late catch-up phenomenon. J Am Coll Cardiol 2004;43:69A. 20. Waksman R, Ajani AE, White RL, et al. Five-year follow-up after intracoronary gamma radiation therapy for in-stent restenosis Circulation 2004;109:340-344.[Abstract/Free Full Text] 21. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosisimmediate and long-term clinical and angiographic outcome. Circulation 2002;105:1883-1886.[Abstract/Free Full Text] 22. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting stents after discontinuation of antiplatelet therapy Lancet 2004;364:1519-1521.[CrossRef][Web of Science][Medline]
This article has been cited by other articles:
|
|
|
|
 
A. Menozzi, E. Solinas, P. Ortolani, A. Repetto, F. Saia, G. Piovaccari, A. Manari, E. Magagnini, L. Vignali, E. Bonizzoni, et al.
Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: the long-term SES-SMART clinical study
Eur. Heart J.,
September 1, 2009;
30(17):
2095 - 2101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Leon, D. J. Allocco, K. D. Dawkins, and D. S. Baim
Late Clinical Events After Drug-Eluting Stents: The Interplay Between Stent-Related and Natural History-Driven Events
J. Am. Coll. Cardiol. Intv.,
June 1, 2009;
2(6):
504 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moore, P. Barlis, J. Spiro, G. Ghimire, M. Roughton, C. Di Mario, W. Wallis, C. Ilsley, A. Mitchell, M. Mason, et al.
A Randomized Optical Coherence Tomography Study of Coronary Stent Strut Coverage and Luminal Protrusion With Rapamycin-Eluting Stents
J. Am. Coll. Cardiol. Intv.,
May 1, 2009;
2(5):
437 - 444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Weisz, M. B. Leon, D. R. Holmes Jr, D. J. Kereiakes, J. J. Popma, P. S. Teirstein, S. A. Cohen, H. Wang, D. E. Cutlip, and J. W. Moses
Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial.
J. Am. Coll. Cardiol.,
April 28, 2009;
53(17):
1488 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Margolis
The Excel Stent: A Good DES, But Can We Really Stop Clopidogrel After 6 Months?
J. Am. Coll. Cardiol. Intv.,
April 1, 2009;
2(4):
310 - 311.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Chen, L. V. Crisco, R. Jabara, and S. B. King III
Late Angiographic Stent Thrombosis: The LAST Straw for Drug-Eluting Stents?
Angiology,
January 1, 2009;
59(6):
667 - 675.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. G. Byrne, M. Leacche, D. E. Vaughan, and D. X. Zhao
Hybrid Cardiovascular Procedures
J. Am. Coll. Cardiol. Intv.,
October 1, 2008;
1(5):
459 - 468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Malenka, A. V. Kaplan, F. L. Lucas, S. M. Sharp, and J. S. Skinner
Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
JAMA,
June 25, 2008;
299(24):
2868 - 2876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kelbaek, L. Klovgaard, S. Helqvist, J. F. Lassen, L. R. Krusell, T. Engstrom, H. E. Botker, E. Jorgensen, K. Saunamaki, S. Aljabbari, et al.
Long-Term Outcome in Patients Treated With Sirolimus-Eluting Stents in Complex Coronary Artery Lesions: 3-Year Results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) Trial
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2011 - 2016.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. E. Kip, K. Hollabaugh, O. C. Marroquin, and D. O. Williams
The Problem With Composite End Points in Cardiovascular Studies The Story of Major Adverse Cardiac Events and Percutaneous Coronary Intervention.
J. Am. Coll. Cardiol.,
February 19, 2008;
51(7):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. C. Marroquin, F. Selzer, S. R. Mulukutla, D. O. Williams, H. A. Vlachos, R. L. Wilensky, J.-F. Tanguay, E. M. Holper, J. D. Abbott, J. S. Lee, et al.
A Comparison of Bare-Metal and Drug-Eluting Stents for Off-Label Indications
N. Engl. J. Med.,
January 24, 2008;
358(4):
342 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Dixon, C. L. Grines, and W. W. O'Neill
The Year in Interventional Cardiology
J. Am. Coll. Cardiol.,
July 17, 2007;
50(3):
270 - 285.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. Campo, C. Arcozzi, P. Malagutti, R. Carletti, F. Ferrari, D. Barbieri, G. Parrinello, G. Percoco, and R. Ferrari
Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction: Results From the STRATEGY Study
J. Am. Coll. Cardiol.,
July 10, 2007;
50(2):
138 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip, S. Windecker, R. Mehran, A. Boam, D. J. Cohen, G.-A. van Es, P. Gabriel Steg, M.-a. Morel, L. Mauri, P. Vranckx, et al.
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Circulation,
May 1, 2007;
115(17):
2344 - 2351.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
April 1, 2007;
12(2):
63 - 64.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Camenzind, P. G. Steg, and W. Wijns
A Cause for Concern
Circulation,
March 20, 2007;
115(11):
1440 - 1455.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-P. B.-L. Rocca, C. Kaiser, M. Pfisterer, and on behalf of the BASKET Investigators
Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET)
Eur. Heart J.,
March 2, 2007;
28(6):
719 - 725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Meier, R. Zbinden, M. Togni, P. Wenaweser, S. Windecker, B. Meier, and C. Seiler
Coronary Collateral Function Long After Drug-Eluting Stent Implantation
J. Am. Coll. Cardiol.,
January 2, 2007;
49(1):
15 - 20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Nordmann, M. Briel, and H. C. Bucher
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis
Eur. Heart J.,
December 1, 2006;
27(23):
2784 - 2814.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Tsimikas
Drug-Eluting Stents and Late Adverse Clinical Outcomes: Lessons Learned, Lessons Awaited
J. Am. Coll. Cardiol.,
May 16, 2006;
47(10):
2112 - 2115.
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Sigwart
Drug-Eluting Stents Are Safe and Effective: Right or Wrong?
J. Am. Coll. Cardiol.,
April 4, 2006;
47(7):
1361 - 1362.
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Methods